512 related articles for article (PubMed ID: 16118019)
1. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
[TBL] [Abstract][Full Text] [Related]
2. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
3. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.
Honegger A; Malebranche AD; Röthlisberger D; Plückthun A
Protein Eng Des Sel; 2009 Mar; 22(3):121-34. PubMed ID: 19136675
[TBL] [Abstract][Full Text] [Related]
4. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
5. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
6. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.
Werther WA; Gonzalez TN; O'Connor SJ; McCabe S; Chan B; Hotaling T; Champe M; Fox JA; Jardieu PM; Berman PW; Presta LG
J Immunol; 1996 Dec; 157(11):4986-95. PubMed ID: 8943405
[TBL] [Abstract][Full Text] [Related]
7. Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4.
Fontayne A; Vanhoorelbeke K; Pareyn I; Van Rompaey I; Meiring M; Lamprecht S; Roodt J; Desmet J; Deckmyn H
Thromb Haemost; 2006 Nov; 96(5):671-84. PubMed ID: 17080226
[TBL] [Abstract][Full Text] [Related]
8. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework.
Kügler M; Stein C; Schwenkert M; Saul D; Vockentanz L; Huber T; Wetzel SK; Scholz O; Plückthun A; Honegger A; Fey GH
Protein Eng Des Sel; 2009 Mar; 22(3):135-47. PubMed ID: 19188138
[TBL] [Abstract][Full Text] [Related]
9. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops.
Xiang J; Sha Y; Jia Z; Prasad L; Delbaere LT
J Mol Biol; 1995 Oct; 253(3):385-90. PubMed ID: 7473721
[TBL] [Abstract][Full Text] [Related]
10. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling.
Eigenbrot C; Randal M; Presta L; Carter P; Kossiakoff AA
J Mol Biol; 1993 Feb; 229(4):969-95. PubMed ID: 8095303
[TBL] [Abstract][Full Text] [Related]
11. Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin.
He XY; Xu Z; Melrose J; Mullowney A; Vasquez M; Queen C; Vexler V; Klingbeil C; Co MS; Berg EL
J Immunol; 1998 Jan; 160(2):1029-35. PubMed ID: 9551944
[TBL] [Abstract][Full Text] [Related]
12. Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences.
Singer II; Kawka DW; DeMartino JA; Daugherty BL; Elliston KO; Alves K; Bush BL; Cameron PM; Cuca GC; Davies P
J Immunol; 1993 Apr; 150(7):2844-57. PubMed ID: 8095956
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.
Fan ZC; Shan L; Goldsteen BZ; Guddat LW; Thakur A; Landolfi NF; Co MS; Vasquez M; Queen C; Ramsland PA; Edmundson AB
J Mol Recognit; 1999; 12(1):19-32. PubMed ID: 10398393
[TBL] [Abstract][Full Text] [Related]
14. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
[TBL] [Abstract][Full Text] [Related]
15. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
[TBL] [Abstract][Full Text] [Related]
16. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.
van den Beucken T; van Neer N; Sablon E; Desmet J; Celis L; Hoogenboom HR; Hufton SE
J Mol Biol; 2001 Jul; 310(3):591-601. PubMed ID: 11439026
[TBL] [Abstract][Full Text] [Related]
17. Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies.
Pedersen JT; Henry AH; Searle SJ; Guild BC; Roguska M; Rees AR
J Mol Biol; 1994 Jan; 235(3):959-73. PubMed ID: 7507176
[TBL] [Abstract][Full Text] [Related]
18. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
[TBL] [Abstract][Full Text] [Related]
19. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
Wang Y; Li X; Chen W
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
[TBL] [Abstract][Full Text] [Related]
20. Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity.
Lee SH; Park DW; Sung ES; Park HR; Kim JK; Kim YS
Mol Immunol; 2010 Jan; 47(4):816-24. PubMed ID: 19864027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]